Astellas Transfers Protopic Marketing Rights In Japan To Maruho
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma said it has transferred marketing rights to Maruho for the atopic dermatitis drug, Protopic (tacrolimus)
Astellas Pharma said it has transferred marketing rights to Maruho for the atopic dermatitis drug, Protopic (tacrolimus). Atellas said it would retain approval rights to production and distribution in Japan. Under the agreement, distribution rights are to be transferred to Maruho in April. (Click here for more) "Firms Join Hands In Marketing Treatment For Atopic Dermatitis" - Asahi Shimbun (Japan) (12/7/10) |